{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:56:29Z","timestamp":1760028989198,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Julie von M\u00fcllens Fond"},{"name":"Region Hovedstadens Research Fund","award":["A7160"],"award-info":[{"award-number":["A7160"]}]},{"DOI":"10.13039\/501100009898","name":"Beckett-Fonden","doi-asserted-by":"publisher","award":["21-2-7785"],"award-info":[{"award-number":["21-2-7785"]}],"id":[{"id":"10.13039\/501100009898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11883-022-01002-0","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T14:21:55Z","timestamp":1643811715000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia"],"prefix":"10.1007","volume":"24","author":[{"given":"Anne","family":"Langsted","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"1002_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol."},{"key":"1002_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/eht273.","journal-title":"Eur Heart J."},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","volume":"57","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953\u201375. https:\/\/doi.org\/10.1194\/jlr.R071233.","journal-title":"J Lipid Res."},{"key":"1002_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412\u201323. https:\/\/doi.org\/10.1001\/jama.2009.1063.","journal-title":"JAMA."},{"key":"1002_CR5","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331\u20139. https:\/\/doi.org\/10.1001\/jama.2009.801.","journal-title":"JAMA."},{"key":"1002_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.038.","journal-title":"J Am Coll Cardiol."},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","volume":"74","author":"A Langsted","year":"2019","unstructured":"Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74:54\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.524.","journal-title":"J Am Coll Cardiol."},{"key":"1002_CR8","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","volume":"40","author":"A Langsted","year":"2019","unstructured":"Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40:2760\u201370. https:\/\/doi.org\/10.1093\/eurheartj\/ehy902.","journal-title":"Eur Heart J."},{"key":"1002_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","volume":"368","author":"G Thanassoulis","year":"2013","unstructured":"Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1109034.","journal-title":"N Engl J Med."},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","volume":"4","author":"A Langsted","year":"2016","unstructured":"Langsted A, Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4:577\u201387. https:\/\/doi.org\/10.1016\/S2213-8587(16)30042-0.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J."},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","volume":"8","author":"RA Hegele","year":"2020","unstructured":"\u2022\u2022 Hegele RA, Boren J, Ginsberg HN, Arca M, Averna M, Binder CJ, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020;8:50\u201367. https:\/\/doi.org\/10.1016\/S2213-8587(19)30264-5. Comprehensive consensus statement including management of clinical familial hypercholesterolemia from the European Atherosclerosis Society.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.14744\/AnatolJCardiol.2019.95038","volume":"23","author":"V Moldovan","year":"2020","unstructured":"Moldovan V, Banescu C, Dobreanu M. Molecular diagnosis methods in familial hypercholesterolemia. Anatol J Cardiol. 2020;23:120\u20137. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2019.95038.","journal-title":"Anatol J Cardiol."},{"key":"1002_CR14","doi-asserted-by":"publisher","first-page":"574474","DOI":"10.3389\/fgene.2020.574474","volume":"11","author":"M Vrablik","year":"2020","unstructured":"\u2022 Vrablik M, Tichy L, Freiberger T, Blaha V, Satny M, Hubacek JA. Genetics of familial hypercholesterolemia: new insights. Front Genet. 2020;11:574474. https:\/\/doi.org\/10.3389\/fgene.2020.574474. Overwiev of genetics in familial hypercholeserolemia","journal-title":"Front Genet."},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","volume":"16","author":"AJ Berberich","year":"2019","unstructured":"\u2022 Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol. 2019;16:9\u201320. https:\/\/doi.org\/10.1038\/s41569-018-0052-6. Overwiev of genetics in familial hypercholeserolemia","journal-title":"Nat Rev Cardiol."},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","volume":"36","author":"J Wang","year":"2016","unstructured":"Wang J, Dron JS, Ban MR, Robinson JF, McIntyre AD, Alazzam M, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. Arterioscler Thromb Vasc Biol. 2016;36:2439\u201345. https:\/\/doi.org\/10.1161\/ATVBAHA.116.308027.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75:2553\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.057.","journal-title":"J Am Coll Cardiol."},{"key":"1002_CR18","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","volume":"141","author":"P Hu","year":"2020","unstructured":"\u2022 Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation. 2020;141:1742\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044795. A comprehensive assessment and estimation of the prevalence of familial hypercholesterolemia in the general population and among in patients with atherosclerotic cardiovascular disease.","journal-title":"Circulation."},{"key":"1002_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","volume":"5","author":"KA Wilemon","year":"2020","unstructured":"Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. 2020;5:217\u201329. https:\/\/doi.org\/10.1001\/jamacardio.2019.5173.","journal-title":"JAMA Cardiol."},{"key":"1002_CR20","doi-asserted-by":"publisher","unstructured":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991:303:893\u20136. https:\/\/doi.org\/10.1136\/bmj.303.6807.893.","DOI":"10.1136\/bmj.303.6807.893"},{"key":"1002_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","volume":"72","author":"RR Williams","year":"1993","unstructured":"Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171\u20136. https:\/\/doi.org\/10.1016\/0002-9149(93)90155-6.","journal-title":"Am J Cardiol."},{"key":"1002_CR22","unstructured":"World Health Organization. Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. Accessed on: 28\u201310\u20132021."},{"key":"1002_CR23","doi-asserted-by":"publisher","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","volume":"3","author":"JC Defesche","year":"2017","unstructured":"Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093. https:\/\/doi.org\/10.1038\/nrdp.2017.93.","journal-title":"Nat Rev Dis Primers."},{"key":"1002_CR24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","volume":"139","author":"G Pare","year":"2019","unstructured":"Pare G, Caku A, McQueen M, Anand SS, Enas E, Clarke R, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139:1472\u201382. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034311.","journal-title":"Circulation."},{"key":"1002_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/01.cir.102.10.1082","volume":"102","author":"J Danesh","year":"2000","unstructured":"Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082\u20135. https:\/\/doi.org\/10.1161\/01.cir.102.10.1082.","journal-title":"Circulation."},{"key":"1002_CR26","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0902604.","journal-title":"N Engl J Med."},{"key":"1002_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","volume":"67","author":"PR Kamstrup","year":"2021","unstructured":"Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2021;67:154\u201366. https:\/\/doi.org\/10.1093\/clinchem\/hvaa247.","journal-title":"Clin Chem."},{"key":"1002_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1373\/clinchem.2019.306738","volume":"65","author":"DC Chan","year":"2019","unstructured":"Chan DC, Pang J, Hooper AJ, Bell DA, Burnett JR, Watts GF. Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic? Clin Chem. 2019;65:1258\u201366. https:\/\/doi.org\/10.1373\/clinchem.2019.306738.","journal-title":"Clin Chem."},{"key":"1002_CR29","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","volume":"75","author":"M Trinder","year":"2020","unstructured":"Trinder M, DeCastro ML, Azizi H, Cermakova L, Jackson LM, Frohlich J, et al. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia. J Am Coll Cardiol. 2020;75:2682\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.065.","journal-title":"J Am Coll Cardiol."},{"key":"1002_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.08.009","author":"V Marco-Benedi","year":"2021","unstructured":"Marco-Benedi V, Cenarro A, Laclaustra M, Larrea-Sebal A, Jarauta E, Lamiquiz-Moneo I, et al. Lipoprotein(a) in hereditary hypercholesterolemia: influence of the genetic cause, defective gene and type of mutation. Atherosclerosis. 2021. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.08.009.","journal-title":"Atherosclerosis."},{"key":"1002_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jacl.2017.02.010","volume":"11","author":"B Sjouke","year":"2017","unstructured":"Sjouke B, Yahya R, Tanck MWT, Defesche JC, de GJ, Wiegman A, et al. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. J Clin Lipidol. 2017;11:507\u201314. https:\/\/doi.org\/10.1016\/j.jacl.2017.02.010.","journal-title":"J Clin Lipidol."},{"key":"1002_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/01.cir.79.2.225","volume":"79","author":"H Mabuchi","year":"1989","unstructured":"Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 1989;79:225\u201332. https:\/\/doi.org\/10.1161\/01.cir.79.2.225.","journal-title":"Circulation."},{"key":"1002_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacl.2016.06.007","volume":"10","author":"S Beliard","year":"2016","unstructured":"Beliard S, Millier A, Carreau V, Carrie A, Moulin P, Fredenrich A, et al. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: analysis of 734 French patients. J Clin Lipidol. 2016;10:1129\u201336. https:\/\/doi.org\/10.1016\/j.jacl.2016.06.007.","journal-title":"J Clin Lipidol."},{"key":"1002_CR34","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1373\/clinchem.2005.055228","volume":"51","author":"DT Holmes","year":"2005","unstructured":"Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005;51:2067\u201373. https:\/\/doi.org\/10.1373\/clinchem.2005.055228.","journal-title":"Clin Chem."},{"key":"1002_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ijcard.2015.08.146","volume":"201","author":"DC Chan","year":"2015","unstructured":"Chan DC, Pang J, Hooper AJ, Burnett JR, Bell DA, Bates TR, et al. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol. 2015;201:633\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.146.","journal-title":"Int J Cardiol."},{"key":"1002_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2017.03.021","volume":"260","author":"S Li","year":"2017","unstructured":"Li S, Wu NQ, Zhu CG, Zhang Y, Guo YL, Gao Y, et al. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis. 2017;260:67\u201374. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.021.","journal-title":"Atherosclerosis."},{"key":"1002_CR37","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","volume":"63","author":"R Alonso","year":"2014","unstructured":"Alonso R, Andres E, Mata N, Fuentes-Jimenez F, Badimon L, Lopez-Miranda J, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63:1982\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.063.","journal-title":"J Am Coll Cardiol"},{"key":"1002_CR38","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","volume":"135","author":"I Perez d","year":"2017","unstructured":"Perez d I, Alonso R, Mata N, Fernandez-Perez C, Muniz O, Diaz-Diaz JL, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135:2133\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024541.","journal-title":"Circulation."},{"key":"1002_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jacl.2019.04.006","volume":"13","author":"M Paquette","year":"2019","unstructured":"\u2022 Paquette M, Bernard S, Thanassoulis G, Baass A. LPA genotype is associated with premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol. 2019;13:627\u201333. https:\/\/doi.org\/10.1016\/j.jacl.2019.04.006. This study finds that the LPA variant rs10455872 is a predictor of premature cardiovascular disease risk in familial hypercholesterolemia.","journal-title":"J Clin Lipidol."},{"key":"1002_CR40","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jacl.2018.07.014","volume":"12","author":"AW Zawacki","year":"2018","unstructured":"Zawacki AW, Dodge A, Woo KM, Ralphe JC, Peterson AL. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. J Clin Lipidol. 2018;12:1445\u201351. https:\/\/doi.org\/10.1016\/j.jacl.2018.07.014.","journal-title":"J Clin Lipidol."},{"key":"1002_CR41","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jacl.2019.06.011","volume":"13","author":"C Pavanello","year":"2019","unstructured":"Pavanello C, Pirazzi C, Bjorkman K, Sandstedt J, Tarlarini C, Mosca L, et al. Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. J Clin Lipidol. 2019;13:778\u201387. https:\/\/doi.org\/10.1016\/j.jacl.2019.06.011.","journal-title":"J Clin Lipidol."},{"key":"1002_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","volume":"73","author":"KL Ellis","year":"2019","unstructured":"Ellis KL, Perez d I, Alonso R, Fuentes F, Watts GF, Mata P. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol. 2019;73:1029\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.037.","journal-title":"J Am Coll Cardiol"},{"key":"1002_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jacl.2019.01.010","volume":"13","author":"MP Bogsrud","year":"2019","unstructured":"Bogsrud MP, Graesdal A, Johansen D, Langslet G, Hovland A, Arnesen KE, et al. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. J Clin Lipidol. 2019;13:279\u201386. https:\/\/doi.org\/10.1016\/j.jacl.2019.01.010.","journal-title":"J Clin Lipidol."},{"key":"1002_CR44","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"SS Gidding","year":"2015","unstructured":"Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167\u201392. https:\/\/doi.org\/10.1161\/CIR.0000000000000297.","journal-title":"Circulation."},{"key":"1002_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5551\/jat.CR003","volume":"25","author":"M Harada-Shiba","year":"2018","unstructured":"Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25:751\u201370. https:\/\/doi.org\/10.5551\/jat.CR003.","journal-title":"J Atheroscler Thromb."},{"key":"1002_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jacl.2014.01.002","volume":"8","author":"GF Watts","year":"2014","unstructured":"Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014;8:148\u201372. https:\/\/doi.org\/10.1016\/j.jacl.2014.01.002.","journal-title":"J Clin Lipidol."},{"key":"1002_CR47","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.cjca.2018.09.005","volume":"34","author":"LR Brunham","year":"2018","unstructured":"Brunham LR, Ruel I, Aljenedil S, Riviere JB, Baass A, Tu JV, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. Can J Cardiol. 2018;34:1553\u201363. https:\/\/doi.org\/10.1016\/j.cjca.2018.09.005.","journal-title":"Can J Cardiol."},{"key":"1002_CR48","doi-asserted-by":"publisher","first-page":"408","DOI":"10.12809\/hkmj187215","volume":"24","author":"B Tomlinson","year":"2018","unstructured":"Tomlinson B, Chan JC, Chan WB, Chen WW, Chow FC, Li SK, et al. Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoin. Hong Kong Med J. 2018;24:408\u201315. https:\/\/doi.org\/10.12809\/hkmj187215.","journal-title":"Hong Kong Med J."},{"key":"1002_CR49","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehq386.","journal-title":"Eur Heart J."},{"key":"1002_CR50","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","volume":"72","author":"AC Sturm","year":"2018","unstructured":"Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018;72:662\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2018.05.044.","journal-title":"J Am Coll Cardiol."},{"key":"1002_CR51","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425\u201337. https:\/\/doi.org\/10.1093\/eurheartj\/ehv157.","journal-title":"Eur Heart J."},{"key":"1002_CR52","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","volume":"13","author":"DP Wilson","year":"2019","unstructured":"Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374\u201392. https:\/\/doi.org\/10.1016\/j.jacl.2019.04.010.","journal-title":"J Clin Lipidol."},{"key":"1002_CR53","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41:2275\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310.","journal-title":"Eur Heart J."},{"key":"1002_CR54","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation."},{"key":"1002_CR55","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2337\/dc20-2842","volume":"44","author":"GG Schwartz","year":"2021","unstructured":"Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, et al. Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment. Diabetes Care. 2021;44:1219\u201327. https:\/\/doi.org\/10.2337\/dc20-2842.","journal-title":"Diabetes Care."},{"key":"1002_CR56","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","volume":"41","author":"M Szarek","year":"2020","unstructured":"Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41:4245\u201355. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa649.","journal-title":"Eur Heart J."},{"key":"1002_CR57","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-01002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:30:17Z","timestamp":1650594617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-01002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-01002-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"type":"print","value":"1523-3804"},{"type":"electronic","value":"1534-6242"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"23 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Nordestgaard reports personal fees from AstraZeneca, Sanofi, Regeneron, Akcea, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Silence Therapeutics, outside the submitted work. Dr. Langsted has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All individuals in the Copenhagen general Population Study gave written, informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}